Company intelligence / Profile preview

HealthBaby

Shatin, Hong Kong

Ownership: Private
Development stage: Other

Overview

HealthBaby has released 45 cord blood units for treatment of various health conditions. Three patients were successfully treated with their own cord blood (two with cerebral palsy, one with neuroblastoma). One recipient received sibling cord blood transplant for Fanconi anemia, and one received allogeneic cord blood transplant for thalassemia major.

Therapeutic areas: HematologyOncologyNeurology
Modalities: Stem cell therapyCell therapy
Industry: Biotech

Partnerships

Hong Kong public cord blood bankInternational and local universities for research projects including HPV vaccine studies and influenza research

Beyond the preview

Go deeper on HealthBaby.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HealthBaby.

Explore the full profile